When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
MIST - Milestone Scientific down 75% after hours on failed etripamil study
Milestone Pharmaceuticals Inc.
A Phase 3 clinical trial, NODE-301, evaluating Milestone Scientific's (NASDAQ:MIST) etripamil nasal spray in patients with paroxysmal supraventricular tachycardia (PSVT) (abnormally fast heartbeat that starts above the lower chambers of the heart) did not achieve the primary endpoint.
More news on: Milestone Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move,